Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.69 |
| ▸ | FKBP1A | P62942 | 10/20 | 0.64 |
| ▸ | ACE | P12821 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9464405 | 0.93 | PREP (0.67) | PREPFKBP1AACEALDH1A1CYP3A4 | |
| SCHEMBL18620837 | 0.93 | PREP (0.67) | PREPFKBP1AACEALDH1A1CYP3A4 | |
| SCHEMBL2228388 | 0.92 | PREP (0.71) | PREPFKBP1AACEALDH1A1KMT2A | |
| SCHEMBL11764594 | 0.92 | PREP (0.71) | PREPFKBP1AACEALDH1A1KMT2A | |
| SCHEMBL1189713 | 0.90 | FKBP1A (0.63) | PREPFKBP1AACEALDH1A1CYP3A4 | |
| SCHEMBL11033242 | 0.90 | PREP (0.68) | PREPFKBP1AACEALDH1A1CYP3A4 | |
| SCHEMBL9518270 | 0.90 | PREP (0.68) | PREPFKBP1AACEALDH1A1CYP3A4 | |
| SCHEMBL1997241 | 0.89 | FKBP1A (0.64) | PREPFKBP1AACE | |
| SCHEMBL6787227 | 0.89 | FKBP1A (0.64) | PREPFKBP1AACE | |
| SCHEMBL1997238 | 0.89 | FKBP1A (0.64) | PREPFKBP1AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113929736-B | Gly-Pro-Arg-Pro-oxaminocarbonyl warfarin, synthesis, activity and application thereof | 首都医科大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-113929739-B | Gly-Pro-Arg-Pro-NH ethoxycarbonyl warfarin, synthesis, activity and application thereof | 首都医科大学 | 2023-07-28 | — | — | CN | disclosed |
| US-7863304-B2 | Analogs of glycyl-prolyl-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-01-04 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | PREP 24/4885FKBP1A 524/4885ACE 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.